OBJECTIVE: To evaluate the protective rate and the variation of HFRS-IgG on hemorrhagical fever with renal syndrome (HFRS) vaccine. METHODS: Cluster, random sampling and cross-sectional study were used to assess the protective rate of HFRS vaccination. Level of HFRS-IgG was detected with ELISA in epidemic and non-epidemic areas of HFRS. RESULTS: Curve equation was obtained as Yprotective rate=(0.863+0.283/Xvaccination term)×100% by protective rate with vaccination term. Protective rates showed a reducing trend, 90% after 7-8 years of vaccination, 88% after 10 years, and 94% on average. Absorbance (A) value of HFRS-IgG was 4 times higher in persons with vaccination than those without, in the epidemic area. Higher antibody level could be obtained after primary vaccination, but the level of antibody had a 50% reduction after 5-10 years of vaccination, and a 60% reduction after 10 years of vaccination. CONCLUSION: HFRS antibody had a 50% reduction after 5-10 years of vaccination. The protective rate of HFRS vaccination had a 90% loss, after 7-8 years of vaccination. Booster dose was necessary after 7 years of vaccination.
OBJECTIVE: To evaluate the protective rate and the variation of HFRS-IgG on hemorrhagical fever with renal syndrome (HFRS) vaccine. METHODS: Cluster, random sampling and cross-sectional study were used to assess the protective rate of HFRS vaccination. Level of HFRS-IgG was detected with ELISA in epidemic and non-epidemic areas of HFRS. RESULTS: Curve equation was obtained as Yprotective rate=(0.863+0.283/Xvaccination term)×100% by protective rate with vaccination term. Protective rates showed a reducing trend, 90% after 7-8 years of vaccination, 88% after 10 years, and 94% on average. Absorbance (A) value of HFRS-IgG was 4 times higher in persons with vaccination than those without, in the epidemic area. Higher antibody level could be obtained after primary vaccination, but the level of antibody had a 50% reduction after 5-10 years of vaccination, and a 60% reduction after 10 years of vaccination. CONCLUSION: HFRS antibody had a 50% reduction after 5-10 years of vaccination. The protective rate of HFRS vaccination had a 90% loss, after 7-8 years of vaccination. Booster dose was necessary after 7 years of vaccination.
Authors: P B Yu; H Y Tian; C F Ma; C A Ma; J Wei; X L Lu; Z Wang; S Zhou; S Li; J H Dong; J R Xu; B Xu; J J Wang Journal: Epidemiol Infect Date: 2014-05-01 Impact factor: 4.434
Authors: Tamara K Dzagurova; Alexandra A Siniugina; Aidar A Ishmukhametov; Maria S Egorova; Svetlana S Kurashova; Maria V Balovneva; Andrey A Deviatkin; Petr E Tkachenko; Oksana A Leonovich; Evgeny A Tkachenko Journal: Front Cell Infect Microbiol Date: 2020-11-02 Impact factor: 5.293